Drugs Made In America Acquisition II Corp.
DMII- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002040475
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
70
- +2 vs. Q1 2026
- Total value $461.22M
Superinvestors holding DMII
0
- None of the superinvestors held DMII at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by DMII insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | Sep 26, 2025 | Stockwell LynnCEO and Exe. Chair of Board | PPurchaseOrdinary shares | +700K | – | – | 15.08M | +4.9% | SEC |
| Oct 1, 2025 | Sep 26, 2025 | Stockwell LynnCEO and Exe. Chair of Board | SSaleOrdinary shares | −7.97M | – | – | 6.71M | −54.3% | SEC |
| Oct 1, 2025 | Sep 26, 2025 | Stockwell LynnCEO and Exe. Chair of Board | PPurchaseOrdinary shares · Derivative | +70K | – | – | 700K | – | SEC |
| Oct 1, 2025 | Sep 26, 2025 | Drugs Made In America Acquisition II LLC10% Owner | PPurchaseOrdinary shares | +700K | – | – | 15.08M | +4.9% | SEC |
| Oct 1, 2025 | Sep 26, 2025 | Drugs Made In America Acquisition II LLC10% Owner | SSaleOrdinary shares | −7.97M | – | – | 6.71M | −54.3% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in DMII at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 2,787,998 | $28.05M | 0.81% | +190,075+7.3% | Added |
| Magnetar Financial LLC | 2,700,000 | $27.16M | 0.25% | 00.0% | Unchanged |
| MMCAP International Inc. SPC | 2,700,000 | $27.16M | 2.30% | 00.0% | Unchanged |
| GLAZER CAPITAL, LLC | 2,343,278 | $23.57M | 0.58% | −6,483−0.3% | Reduced |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,241,215 | $22.57M | 0.77% | +2,016,211+896.1% | Added |